(Lausanne, February 3rd) - Results from the first clinical trial of a therapeutic cancer vaccine combining the synthetic bacterial DNA sequence, CpG 7909 (ProMune
TM, Coley Pharmaceutical), with a peptide antigen were reported today in the Journal of Clinical Investigation. The paper shows that the CpG 7909 DNA sequence is safe, and increases the immune system's ability to recognize and destroy cancer cells. The Phase I study was conducted by the Lausanne Branch of the Ludwig Institute for Cancer Research (LICR) at the Lausanne University Hospital in Switzerland, in the framework of the international Cancer Vaccine Collaborative (CVC), a partnership established by the New York-based Cancer Research Institute (CRI) and the LICR.
"What we're doing is testing a novel adjuvant, a compound that stimulates the immunological response to a vaccine, which is essentially tricking the immune system into thinking the vaccine is a bacterial infection," says lead author Dr. Daniel Speiser from the LICR Lausanne Branch. "The immune system mounts a response against the peptide antigen, the cancer-specific target, in the vaccine, and thus also against the antigen on the cancer cells."
The vaccine, combining the CpG 7909 adjuvant and Incomplete Freund's Adjuvant (IFA) with a synthetic peptide (protein fragment) from a melanoma antigen known as Melan-A/MART-1, induced CD8+ T cells that specifically recognized cells displaying Melan-A/MART-1 on their surface. This T cell response occurred in all eight patients in the trial. Responses were one order of magnitude higher than those observed in eight patients who received the Melan-A/MART-1 antigen with IFA but without CpG 7909 in previous studies.
According to Dr. Jill O'Donnell-Tormey, the Executive Director of CRI, the trial is part of the CVC's systematic, coordinated vaccine development approach that compares single vaccine variables in parallel. "We've identified many cancer antigens, and the challe
'"/>
Contact: Sarah L. White, Ph.D.
swhite@licr.org
1-212-450-1543
Ludwig Institute for Cancer Research
3-Feb-2005
Page: 1 2 Related medicine news :1.
Pitt marks 50th anniversary of its Salk polio vaccine with reunion, scientific symposium2.
NIAID initiates trial of experimental avian flu vaccine3.
Study finds majority of women willing to accept cervical cancer vaccine for self and children4.
Invasive pneumonia and antibiotic resistance decreased after childhood vaccine introduced5.
Earlier use of prostate cancer vaccines urged by Hopkins scientists6.
Researchers close in on breast cancer vaccine7.
EuroVacc 02 HIV vaccine trial begins in February 20058.
Varicella vaccine effective on chicken pox; Impact on herpes zoster unclear9.
HIV vaccine trial breaks ground for future research10.
First US kidney cancer vaccine trial underway at Columbia11.
NIAID begins enrolling volunteers for novel HIV vaccine study